Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.32 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.32 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.31 |
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.31 |
| ▸ | CACNB3 | P54284 | 1/20 | 0.31 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.31 |
| ▸ | PGR | P06401 | 1/20 | 0.31 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.31 |
| ▸ | HTR2B | P41595 | 1/20 | 0.31 |
| ▸ | CACNA2D2 | Q9NY47 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7901849 | 0.82 | TERT (0.42) | HDAC2PGRTDP1 | |
| SCHEMBL7911935 | 0.82 | TERT (0.42) | HDAC2PGRTDP1 | |
| SCHEMBL23829791 | 0.82 | HDAC2 (0.40) | HDAC2PGR | |
| SCHEMBL23829790 | 0.82 | HDAC2 (0.40) | HDAC2PGR | |
| SCHEMBL5981223 | 0.78 | F7 (0.48) | PGRTDP1 | |
| SCHEMBL1705896 | 0.78 | F7 (0.48) | PGRTDP1 | |
| SCHEMBL1705893 | 0.78 | F7 (0.48) | PGRTDP1 | |
| SCHEMBL23922597 | 0.78 | ALDH1A1 (0.43) | HDAC2 | |
| SCHEMBL6439563 | 0.78 | SLC22A6 (0.43) | HDAC2SLC22A6CACNA2D1CACNB3CACNA1C | |
| SCHEMBL6439560 | 0.78 | SLC22A6 (0.43) | HDAC2SLC22A6CACNA2D1CACNB3CACNA1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11149062-B2 | HDAC inhibitors and methods of treatment using the same | UWM RESEARCH FOUNDATION, INC. (US) | 2021-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11149062-B2 | HDAC inhibitors and methods of treatment using the same | HDAC4, HDAC2, HDAC8 | HDAC2 2/4885ITGB3 3852/4885ITGA2B 2041/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.